Panitumumab: In the treatment of metastatic colorectal cancer

Drugs

Volumn 66, Issue 15, 2006, Pages 2005-2014

  Hoy, Sheridan M ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PANITUMUMAB;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE COURSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FOLLOW UP; HUMAN; HYPOMAGNESEMIA; METASTASIS; NAUSEA; PARONYCHIA; SKIN TOXICITY; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33751083588     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666150-00011     Document Type: Article

References (37)

1. World Health Organization. Cancer [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs297/en/print.html [Accessed 2006 May 18]
2. Labianca RF, Beretta GD, Pessi MA. Colorectal cancer: disease management considerations. Drugs 2001; 61 (12): 1751-64
3. Jefford M, Zalcberg J. Recent advances in the systemic therapy of metastatic colorectal cancer. Am J Cancer 2005; 4 (1): 15-34
4. Coutinho AK, Rocha Lima CMS. Metastatic colorectal cancer: systemic treatment in the new millennium. Cancer Control 2003; 10 (3): 224-38
5. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000 Sep 2; 321 (7260): 531-5
6. Alekshun T, Garrett C. Targeted therapies in the treatment of colorectal cancers. Cancer Control 2005 Apr; 12 (2): 105-10
7. Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 2005; 103 (12): 2435-46
8. McWilliams RR, Erlichman C. Novel therapeutics in colorectal cancer. Dis Colon Rectum 2005; 48 (8): 1632-50
9. Ranson M. Technology evaluation: ABX-EGF, Abgenix/Amgen. Curr Opin Mol Ther 2003 Oct; 5 (5): 541-6
10. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004 Dec; 11 (4): 689-708
11. Veronese ML, O'Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 2004 Jun; 40 (9): 1292-301
12. Levene AP, Singh G, Palmieri C. Therapeutic monoclonal antibodies in oncology. J R Soc Med 2005; 98 (4): 146-52
13. Yang X-D, Jia X-C, Corvalan JRF, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17-23
14. Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 2006 Jan-Feb; 29 (1): 1-9
15. Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004 Mar 1; 58 (3): 984-90
16. Amgen. VectibixTM [panitumumab] prescribing information [online]. Available from URL: http://www.fda.gov/ [Accessed 2006 Oct 3]
17. Yang X, Jia X, Corvalan JR, et al. Therapeutic potential of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer treatment [abstract no. 183]. 36th Proc Am Soc Clin Oncol 2000 May 20; 19: 48a
18. Foltz IN, King CT, Liang M, et al. Panitumumab induces internalization of the epidermal growth factor receptor [abstract no. B43 plus poster]. 17th American Association for Cancer Research-National Cancer Institute-European Organisation for the Research and Treatment of Cancer (AACR-NCI EORTC) International Conference on Molecular Targets and Cancer Therapeutics; 2005 Nov 14-18; Philadelphia (PA), 136
19. Bancroft CC, Chen Z, Yeh J, et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002 Jun 1; 99 (4): 538-48
20. Freeman D, McDorman K, Bush T, et al. Mono- and combination-therapeutic activity of panitumumab on human A431 epidermoid and HT-29 colon carcinoma xenografts: correlation with pharmacodynamic parameters [abstract no. 313]. EJC Supplements 2004; 2 (8): 95-6. Plus poster presented at the 16th European Organisation for the Research and Treatment of Cancer National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Symposium on Molecular Targets and Cancer Therapeutics; 2004 Sep 28-Oct 1; Geneva
21. Starnes C, Freeman D, Bush T, et al. Antitumor activity of AMG 706, a novel tyrosine kinase inhibitor, in combination with panitumumab, a fully human antibody targeting the EGF receptor, against multiple established human tumor xenograft models in nude mice [abstract no. B73 plus poster]. 17th European Organisation for the Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Conference on Molecular Targets and Cancer Therapeutics; 2005 Nov 14-18; Philadelphia (PA), 144
22. Roskos L, Lohner M, Osborn K, et al. Low pharmacokinetic variability facilitates optimal dosing of ABX-EGF in cancer patients [abstract no. 362]. Proc Am Soc Clin Oncol 2002; 21 (Pt 1): 91a. Plus poster presented at the 38th American Society of Clinical Oncology (ASCO) Annual Meeting; 2002 May 18 to 21; Orlando (FL)
23. Arends R, Yang BB, Schwab G, et al. Flexible dosing schedules of panitumumab (ABX-EGF) in cancer patients [abstract no. 3089]. J Clin Oncol 2005 Jun 1; 23 (16 Suppl. Pt I): 214
24. Weiner LM, Belldegrun A, Rowinsky E, et al. Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies [abstract no. 3059]. J Clin Oncol 2005; 23 (16 Suppl. Pt I): 206s. Plus poster presented at the 41st American Society of Clinical Oncology (ASCO) Annual Meeting; 2005 May 13-17; Atlanta (GA)
25. Yang B-B, Hecht JR, Malik I, et al. Pharmacokinetics of panitumumab and irinotecan were not altered after first-line panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin in metatstatic colorectal cancer patients [abstract no. 311P]. Ann Oncol 2004; 15 Suppl. 3: iii83
26. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004 Aug 1; 22 (15): 3003-15
27. Peeters M, Van Custem E, Siena S, et al. A phase III, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) versus BSC alone in patients with metastatic colorectal cancer [abstract no. CP-1]. Plus oral presentation at 97th Annual Meeting of the American Association for Cancer Research; 2006 Apr 1-5; Washington, DC
28. Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥10% epidermal growth factor receptor (EGFr). J Clin Oncol 2006; 24 (18 Suppl. Pt 1): 158s. Plus poster presented at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting; 2006 Jun 2-6; Atlanta (GA)
29. Hecht J, Mitchell E, Baranda J, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (<1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr) [abstract no. 3547]. J Clin Oncol 2006; 24 (18 Suppl. Pt 1): 157s. Plus poster presented at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting; 2006 Jun 2-6; Atlanta (GA)
30. Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer [abstract no. 3520]. J Clin Oncol 2005; 23 (16 Suppl. Pt I): 251. Plus poster presented at the 41st American Society of Clinical Oncology (ASCO) Annual Meeting; 2005 May 13-17; Orlando (FL)
31. Humblet Y, Van Custem E, Peeters M, et al. Panitumumab for the treatment of metastatic colorectal cancer (mCRC): a multicenter study in patients who failed chemotherapy and best supportive care (BSC) [abstract no. 3250]. Ann Oncol 2006; 17 Suppl. 9: ix114. Plus oral presentation at the 31st European Society of Medical Oncology (ESMO) Annual Meeting; 2006 29 Sep-3 Oct; Istanbul
32. Berlin J, Van Custem E, Peeters M, et al. Safety and efficacy of panitumumab monotherapy in the treatment of metastatic colorectal cancer (MCRC): summary of results across clinical studies. Ann Oncol 2006; 17 Suppl. 9: ix114-5. Plus oral presentation at the 31st European Society of Medical Oncology (ESMO) Annual Meeting; 2006 29 Sep-3 Oct; Istanbul
33. Arteaga CL, Baselga J. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice [letter]. Clin Cancer Res 2003; 9 (5): 1579-89
34. Hecht J, Posey S, Tchekmedyian S, et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan or FOLFIRI for first-line treatment of metastatic colorectal cancer [abstract no. 237]. 3rd Annual Gastrointestinal Cancers Symposium; 2006 Jan 26-28; San Francisco (CA)
35. Berlin J, Posey J, Tchekmedyian S, et al. First line therapy of panitumumab, a fully human antibody, in combination with FOLFIRI for the treatment of metastatic colorectal cancer [abstract no. 653]. EJC Suppl 2005 Oct 2; 3: 185
36. Berlin J, Malik I, Picus J, et al. Panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin in patients with metastatic colorectal cancer. Ann Oncol 2004; 15 (Suppl. 3): 70-1
37. Amgen. FDA Approves VectibixTM to Treat Patients with Metastatic Colorectal Cancer. Media Rel 28 Sep 2006